Quantcast
Last updated on April 19, 2014 at 6:57 EDT

Latest Clostridium Stories

2011-11-01 07:00:00

SAN DIEGO, Nov. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 20th Annual Credit Suisse Healthcare Conference on Thursday, November 10 at 10:00 AM Eastern Time (7:00 AM Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of the presentation will be...

2011-10-25 07:11:00

GREENSBORO, N.C., Oct. 25, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced that data from studies evaluating the dosing and adverse event profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, in the treatment of blepharospasm (eyelid spasms) will be presented at the 115th Annual Meeting of the American Association of Ophthalmology (AAO) in Orlando, Fla. These data include an extension of the Phase III,...

2011-10-21 08:01:00

FRANKFURT AM MAIN, Germany, October 21, 2011 /PRNewswire/ -- At the 5th International Dystonia Symposium (IDS) in Barcelona, Spain (20-22 October 2011), Merz Pharmaceuticals presented important clinical data concerning the long-term, sustained efficacy and safety of XEOMIN(R) for the treatment of patients with dystonia. Dystonia is a particularly debilitating condition where involuntary muscle contractions can cause abnormal twisting, postures or movements, and is the...

2011-10-13 07:00:00

SAN DIEGO, Oct. 13, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that new research findings for DIFICID(TM) (fidaxomicin) tablets will be featured in presentations at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) occurring October 20-23 in Boston. The presentations include one late-breaker highlighting a new analysis of combined results from Optimer's two large clinical studies of DIFICID for the treatment of Clostridium...

2011-10-03 07:00:00

SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 2011 BioCentury Newsmakers in the Biotech Industry conference on Friday, October 21 at 11:00 AM Eastern time. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of the presentation will be available at...

2011-09-23 08:47:00

STAINES, England and SAN DIEGO, California, September 23, 2011 /PRNewswire/ -- Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR(TM) (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea...

2011-09-23 07:00:00

SAN DIEGO, Sept. 23, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR(TM) (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea (CDAD). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) DIFICLIR,...

2011-09-10 14:16:00

Severe botulism cases reported in France linked to these products SILVER SPRING, Md., Sept. 10, 2011 /PRNewswire-USNewswire/ -- The FDA is warning consumers not to eat tapenade or spreadable dried tomato paste manufactured by the French food company La Ruche. French health authorities have reported an outbreak of botulism in France linked to the company's products sold under the brand names "Les delices de Marie-Claire," "Terre de Mistral" and Les Secrets d'Anais." Eight adults are...

2011-09-09 09:02:00

SAN DIEGO, Sept. 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that 11 abstracts reporting new research findings for DIFICID(TM) (fidaxomicin) tablets will be presented at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place September 17-20 in Chicago. DIFICID was approved by the U.S. Food and Drug Administration (FDA) in May of 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18...

2011-09-07 06:00:00

MALVERN, Pa., Sept. 7, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX® (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords. The tolerability profile following concurrent injection of two doses of XIAFLEX into...


Latest Clostridium Reference Libraries

0_d6572564d3305dc462f4641398789e11
2011-04-15 13:32:47

Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...

More Articles (1 articles) »